Annual Drug Patent Expirations for XTAMPZA+ER
Xtampza Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. It is available from one supplier. There are nineteen patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for XTAMPZA ER.
This drug has nineteen patent family members in thirteen countries.
The generic ingredient in XTAMPZA ER is oxycodone. One supplier is listed for this compound. Additional details are available on the oxycodone profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com